Ž Pavletić

739 total citations
22 papers, 563 citations indexed

About

Ž Pavletić is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Ž Pavletić has authored 22 papers receiving a total of 563 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 9 papers in Oncology and 9 papers in Immunology. Recurrent topics in Ž Pavletić's work include Hematopoietic Stem Cell Transplantation (15 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Immune Cell Function and Interaction (5 papers). Ž Pavletić is often cited by papers focused on Hematopoietic Stem Cell Transplantation (15 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Immune Cell Function and Interaction (5 papers). Ž Pavletić collaborates with scholars based in United States, Croatia and Italy. Ž Pavletić's co-authors include Jamés O. Armitage, Anne Kessinger, Philip J. Bierman, Julie M. Vose, Stefano Tarantolo, Michael R. Bishop, Boris Labar, Dan Nemet, James C. Lynch and Mirando Mršić and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Ž Pavletić

22 papers receiving 547 citations

Peers

Ž Pavletić

HEMAT

ONCOL

IMMUN

GENET

PRM

V Altomonte United States

Robert Witherspoon United States

Byoung Kook Kim South Korea

Francesco Grimaldi Italy

Gergely Kriván Hungary

Giuseppe Console Italy

PI Warkentin United States

Ivo Radman Croatia

S.M. Liesenfeld Germany

Mitsutoshi Kurosawa Japan

V Altomonte United States

Ž Pavletić

562 ×1.6

HEMAT

179 ×0.8

ONCOL

302 ×2.0

IMMUN

78 ×0.6

GENET

145 ×1.7

PRM

Citations per year, relative to Ž Pavletić Ž Pavletić (= 1×) peers V Altomonte

Countries citing papers authored by Ž Pavletić

Since Specialization

Citations

This map shows the geographic impact of Ž Pavletić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ž Pavletić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ž Pavletić more than expected).

Fields of papers citing papers by Ž Pavletić

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ž Pavletić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ž Pavletić. The network helps show where Ž Pavletić may publish in the future.

Co-authorship network of co-authors of Ž Pavletić

This figure shows the co-authorship network connecting the top 25 collaborators of Ž Pavletić. A scholar is included among the top collaborators of Ž Pavletić based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ž Pavletić. Ž Pavletić is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Dickinson, John D., Lynette M. Smith, Warren G. Sanger, et al.. (2005). Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia. British Journal of Haematology. 128(4). 460–471. 18 indexed citations

2.

Joshi, S. K., Michael Bishop, James C. Lynch, et al.. (2003). Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: Results from a randomized double-blind study. Cytotherapy. 5(6). 542–552. 5 indexed citations

3.

Wang, Peng, Ž Pavletić, & S. K. Joshi. (2002). Increased Apoptosis in B-chronic Lymphocytic Leukemia Cells as a Result of Cyclin D3 Down Regulation. Leukemia & lymphoma. 43(9). 1827–1835. 10 indexed citations

4.

Sharp, John, Anne Kessinger, James C. Lynch, Ž Pavletić, & S. K. Joshi. (2000). Blood Stem Cell Transplantation: Factors Influencing Cellular Immunological Reconstitution. Journal of Hematotherapy & Stem Cell Research. 9(6). 971–981. 3 indexed citations

5.

Pavletić, Ž, et al.. (2000). Increased Cytotoxicity Against B-Chronic Lymphocytic Leukemia by Cellular Manipulations: Potentials for Therapeutic Use. Leukemia & lymphoma. 39(5-6). 573–582. 6 indexed citations

6.

Bishop, Michael R., Stefano Tarantolo, Robert B. Geller, et al.. (2000). A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 96(1). 80–85. 71 indexed citations

7.

Bishop, Michael R., Stefano Tarantolo, Robert B. Geller, et al.. (2000). A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 96(1). 80–85. 69 indexed citations

8.

Pavletić, Ž, Philip J. Bierman, Julie M. Vose, et al.. (1998). High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Annals of Oncology. 9(9). 1023–1026. 58 indexed citations

9.

Haire, William D., Elizabeth Ruby, L. Clifton Stephens, et al.. (1998). A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 4(3). 142–150. 17 indexed citations

10.

Bishop, Michael R., Stefano Tarantolo, John D. Jackson, et al.. (1997). Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor.. Journal of Clinical Oncology. 15(4). 1601–1607. 24 indexed citations

11.

Pavletić, Ž, Michael R. Bishop, Stefano Tarantolo, et al.. (1997). Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies.. Journal of Clinical Oncology. 15(4). 1608–1616. 98 indexed citations

12.

Pavletić, Ž & Jamés O. Armitage. (1996). Bone Marrow Transplantation for Cancer—An Update. The Oncologist. 1(3). 159–168. 3 indexed citations

13.

Labar, Boris, Mirando Mršić, Ž Pavletić, et al.. (1993). Prostaglandin E2 for prophylaxis of oral mucositis following BMT.. PubMed. 11(5). 379–82. 68 indexed citations

14.

Labar, Boris, Dan Nemet, Mirando Mršić, et al.. (1992). Antilymphocyte globulin for treatment of pure red cell aplasia after major ABO incompatible marrow transplant.. PubMed. 10(5). 471–2. 20 indexed citations

15.

Nemet, Dan, Boris Labar, Tatjana Kolevska, et al.. (1989). [Treatment of neoplastic hematologic diseases with intensive radio-chemotherapy and transplantation of cryopreserved autologous bone marrow].. PubMed. 111(9-10). 348–53. 1 indexed citations

16.

Nemet, Dan, Boris Labar, Branimir Jakšić, et al.. (1989). High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia.. PubMed. 4 Suppl 3. 42–4. 24 indexed citations

17.

Mršić, Mirando, Boris Labar, Dan Nemet, et al.. (1989). Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia.. PubMed. 4 Suppl 3(2). 137–41. 23 indexed citations

18.

Pavletić, Ž, Mladen Petrovečki, Dan Nemet, et al.. (1989). The significance of immunological monitoring after allogeneic bone marrow transplantation.. PubMed. 4 Suppl 3. 111–111. 1 indexed citations

19.

Labar, Boris, et al.. (1989). Allogeneic bone marrow transplantation for ALL in Zagreb.. PubMed. 4 Suppl 3. 88–9. 4 indexed citations

20.

Pavletić, Ž, Tatjana Kolevska, Ivica Žalud, et al.. (1989). Lymphocyte subsets in normal human bone marrow harvested for routine clinical transplantation.. PubMed. 4(3). 229–32. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact